DEF: Charles River Labs Faces Shareholder Proposal on Primate Imports at 2025 Annual Meeting

Charles River Laboratories International, Inc. is set to hold its 2025 Annual Meeting of Shareholders on May 20, 2025, featuring proposals including director elections, executive compensation, auditor ratification, and a shareholder proposal concerning nonhuman primate imports.

Summary

• Charles River Laboratories International, Inc. will hold its Annual Meeting of Shareholders on May 20, 2025, at Cooley LLP in Boston.
• Shareholders will vote on the election of eleven directors, an advisory vote on executive compensation, ratification of PricewaterhouseCoopers LLP as the independent auditor, and a shareholder proposal regarding nonhuman primate imports.
• The Board of Directors recommends voting for the election of all director nominees, for the advisory vote on executive compensation, for the ratification of PricewaterhouseCoopers LLP, and against the shareholder proposal.
• The record date for determining shareholders eligible to vote is March 21, 2025.
• The proxy statement and annual report are available online at www.criver.com/annual2025.
• The company has been taking restructuring actions that are expected to result in approximately $225 million of cost savings on an annualized basis.
• The company repurchased $100.7 million in common stock in fiscal year 2024 and intends to repurchase approximately $350 million in fiscal year 2025.
• The company's revenue decreased 1.9% and non-GAAP diluted earnings per share decreased 3.3%.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While it highlights the company's resilience and commitment to ethical practices, it also acknowledges financial challenges and a shareholder proposal concerning ethical concerns. The company is taking steps to improve its financial performance and address ethical concerns.

Positives

• Charles River shareholders provided strong majority support for our named executives compensation at our 2024 Annual Meeting of Shareholders (approximately 95% of shares voted in support of this matter).
• Cash flow relating to operating activities of $734.6 million (an increase of 7.4% from 2023).

Negatives

• Our financial performance in fiscal year 2024 demonstrated resilience and stability while facing stabilizing but lower demand trends, and which resulted in a 1.9% decrease in revenue, a 97.8% decrease in GAAP diluted earnings per share, a 3.3% decrease in non-GAAP diluted earnings per share from continuing operations.

Risks

• The company faces risks related to operational regulatory matters, such as quality control and data privacy.
• The company faces risks related to the NHP supply chain.
• The company faces risks related to information security, including risks related to the utilization of artificial intelligence tools.

Future Outlook

The company is actively positioning itself to leverage its leadership position in non-clinical drug development and capitalize on opportunities as the demand environment improves.

Industry Context

The document highlights the challenges faced by biopharmaceutical clients, including restructuring initiatives, budgetary constraints, and the impact of the Inflation Reduction Act, leading to cautious spending on early-stage R&D.

Comparison to Industry Standards

• The company benchmarks executive compensation against a peer group of 37 companies, including Abbott Laboratories, Gilead Sciences, and Thermo Fisher Scientific.
• The company uses a regression model to analyze the competitiveness of executive compensation against the peer group.
• The company's Greenhouse Gas (GHG) emission reduction goals are approved by the Science Based Targets Initiative (SBTi) and are in line with the Paris Climate Agreement and the United Nations Sustainable Development Goals.

Stakeholder Impact

• Shareholders are asked to vote on key decisions regarding the company's direction and governance.
• Employees are impacted by changes in compensation policies and restructuring initiatives.
• Customers benefit from the company's commitment to ethical practices and the development of life-saving drugs.
• The company's actions impact the welfare of research animals and the sustainability of NHP populations.

Next Steps

• Shareholders are urged to vote on the proposals outlined in the proxy statement.
• The Board of Directors will consider the outcome of the advisory vote on executive compensation when making future compensation decisions.
• The Audit Committee will reconsider its appointment of PricewaterhouseCoopers LLP if ratification is not obtained.
• The Board of Directors will continue to monitor and address concerns related to NHP sourcing and animal welfare.

Key Dates

Keywords

Annual Meeting, Shareholder Proposal, Executive Compensation, Board of Directors, Nonhuman Primates, PricewaterhouseCoopers, Director Election, Charles River Labs, Governance, Auditor